Subclinical hypothyroidism during valproic acid therapy in children and adolescents with epilepsy

Neuropediatrics

Volumn 43, Issue 3, 2012, Pages 135-139

  Kim, Se Hee ^a   Chung, Hye Rim ^b   Kim, Seung Hyo ^c   Kim, Hunmin ^b   Lim, Byung Chan ^a   Chae, Jong Hee ^a   Kim, Ki Joong ^a   Hwang, Yong Seung ^a   Hwang, Hee ^b  

^a Seoul National University   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Jeju National University School of Medicine   (South Korea)

Author keywords

Anticonvulsant; Children; Epilepsy; Hypothyroidism; Valproic acid

Indexed keywords

LIOTHYRONINE; THYROTROPIN; THYROXINE; VALPROIC ACID;

ADOLESCENT; ADULT; ANTICONVULSANT THERAPY; ARTICLE; BENIGN CHILDHOOD EPILEPSY; BODY WEIGHT; CHILD; CHILDHOOD DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; FEBRILE CONVULSION; FEMALE; FOCAL EPILEPSY; GENERALIZED EPILEPSY; HUMAN; INFANT; LIOTHYRONINE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; MYOCLONUS EPILEPSY; PRESCHOOL CHILD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SUBCLINICAL HYPOTHYROIDISM; THYROID FUNCTION; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL; TREATMENT DURATION;

ADOLESCENT; ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; EPILEPSY; HUMANS; HYPOTHYROIDISM; SEVERITY OF ILLNESS INDEX; THYROID FUNCTION TESTS; THYROID GLAND; THYROTROPIN; THYROXINE; TRIIODOTHYRONINE; VALPROIC ACID;

EID: 84862771844     PISSN: 0174304X     EISSN: 14391899     Source Type: Journal    
DOI: 10.1055/s-0032-1313913     Document Type: Article

References (21)

1. Abaci A, Saygi M, Yis U, Demir K, Dirik E, Bober E. Metabolic alterations during valproic acid treatment: a prospective study. Pediatr Neurol 2009;41(6):435-439
2. Çaksen H, Dülger H, Cesur Y, Odabaş D, Tuncer O, Ataş B. No effect of long-term valproate therapy on thyroid and parathyroid functions in children. Int J Neurosci 2002;112(11):1371-1374
3. Hirfanoglu T, Serdaroglu A, Camurdan O, et al. Thyroid function and volume in epileptic children using carbamazepine, oxcarbazepine and valproate. Pediatr Int 2007;49(6):822-826
4. Isojärvi JIT, Pakarinen AJ, Myllylä VV. Thyroid function with antiepileptic drugs. Epilepsia 1992;33(1):142-148
5. Verrotti A, Basciani F, Morresi S, Morgese G, Chiarelli F. Thyroid hormones in epileptic children receiving carbamazepine and valproic acid. Pediatr Neurol 2001;25(1):43-46
6. Verrotti A, Laus M, Scardapane A, Franzoni E, Chiarelli F. Thyroid hormones in childrenwith epilepsy during long-term administration of carbamazepine and valproate. Eur J Endocrinol 2009;160(1):81-86
7. Attilakos A, Katsarou E, Prassouli A, et al. Thyroid function in children with epilepsy treated with sodium valproate monotherapy: a prospective study. Clin Neuropharmacol 2009;32(1):32-34
8. Cansu A, Serdaroǧlu A, Çamurdan O, Hirfanoǧlu T, Bideci A, Gücüyener K. The evaluation of thyroid functions, thyroid antibodies, and thyroid volumes in children with epilepsy during short-term administration of oxcarbazepine and valproate. Epilepsia 2006;47(11):1855-1859
9. Castro-Gago M, Novo-Rodríguez MI, Gómez-Lado C, Rodríguez-García J, Rodríguez-Segade S, Eirís-Puñal J. Evolution of subclinical hypothyroidism in children treated with antiepileptic drugs. Pediatr Neurol 2007;37(6):426-430
10. Eirís-Puñal J, Del Río-Garma M, Del Río-Garma MC, Lojo-Rocamonde S, Novo-Rodríguez I, Castro-Gago M. Long-term treatment of children with epilepsy with valproate or carbamazepine may cause subclinical hypothyroidism. Epilepsia 1999;40(12):1761-1766
11. Mikati MA, Tarabay H, Khalil A, Rahi AC, El Banna D, Najjar S. Risk factors for development of subclinical hypothyroidism during valproic acid therapy. J Pediatr 2007;151(2):178-181
12. Vainionpää LK, Mikkonen K, Rättyä J, et al. Thyroid function in girls with epilepsy with carbamazepine, oxcarbazepine, or valproate monotherapy and after withdrawal of medication. Epilepsia 2004;45(3):197-203
13. Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia 2010;51(4):676-685
14. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 2008;29(1):76-131
15. Jung CH, Sung KC, Shin HS, et al. Thyroid dysfunction and their relation to cardiovascular risk factors such as lipid profile, hsCRP, and waist hip ratio in Korea. Korean J Intern Med 2003;18:146-153
16. Löscher W, Schmidt D. Increase of human plasma GABA by sodium valproate. Epilepsia 1980;21(6):611-615
17. Graf WD, Oleinik OE, Glauser TA, Maertens P, Eder DN, Pippenger CE. Altered antioxidant enzyme activities in children with a serious adverse experience related to valproic acid therapy. Neuropediatrics 1998;29(4):195-201
18. Surks MI, Sievert R. Drugs and thyroid function. N Engl J Med 1995;333(25):1688-1694
19. Gharib H, Tuttle RM, Baskin HJ, Fish LH, Singer PA, McDermott MT. Subclinical thyroid dysfunction: a joint statement on management from the American Association of Clinical Endocrinologists, the American Thyroid Association, and the Endocrine Society. J Clin Endocrinol Metab 2005;90(1):581-585, discussion 586-587
20. Jones DD, May KE, Geraci SA. Subclinical thyroid disease. Am J Med 2010;123(6):502-504
21. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 2004;291(2):228-238